Every 8-K that Mind Medicine (MNMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MNMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MNMD filings page.
Definium Therapeutics, Inc. filed an 8‑K to share an updated May 2026 corporate presentation detailing its late‑stage psychedelic‑derived CNS pipeline and financial position. Lead candidate DT120 ODT (lysergide tartrate) is in five Phase 3 studies across generalized anxiety disorder (GAD), major depressive disorder (MDD) and post‑traumatic stress disorder.
The company highlights Phase 2b data in GAD showing a 21.9‑point improvement on the HAM‑A at week 12 for the 100 µg dose, with a 7.7‑point advantage over placebo and 48% remission at week 12, alongside a generally favorable tolerability profile. Three Phase 3 readouts for DT120 are anticipated in 2026, and the FDA has granted Breakthrough Therapy Designation.
Second program DT402 (R(‑)‑MDMA) is in a Phase 2a autism spectrum disorder study after a well‑tolerated Phase 1 trial. Definium reports cash, cash equivalents and investments of $373.4 million and access to a credit facility up to $120 million as of March 31, 2026, supporting a cash runway into 2028, with 109.1 million shares outstanding as of April 30, 2026 and first‑quarter 2026 operating expenses of $59.2 million.
Definium Therapeutics reported that the first patient has been dosed in Ascend, its second Phase 3 pivotal study of DT120 Orally Disintegrating Tablet (DT120 ODT) for major depressive disorder (MDD). The trial will enroll about 175 participants in the U.S. and compare DT120 ODT with placebo.
The primary goal is to measure the change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) score at Week 6 between the 100 µg dose and placebo. Ascend uses a two-part design with a 12-week double-blind period followed by a 40-week open-label extension and includes 100 µg, 50 µg, and placebo arms randomized 2:1:2.
The company anticipates topline data from Ascend’s 12-week double-blind period in 2027 and expects a topline readout from its first Phase 3 MDD trial, Emerge, in late Q2 2026. DT120 ODT is Definium’s proprietary LSD-based fast-dissolve formulation being developed for MDD, generalized anxiety disorder, PTSD, and other serious brain health disorders.
Definium Therapeutics reported a larger net loss as it advances multiple late-stage trials for DT120 ODT in mood and anxiety disorders. Net loss for the quarter ended March 31, 2026 was $77.1 million, compared with $23.3 million a year earlier, driven mainly by higher R&D and G&A spending and a non‑cash warrant fair value loss.
R&D expenses rose to $41.5 million from $23.4 million, reflecting expanded DT120 ODT development and internal research capacity, while G&A increased to $17.7 million from $8.8 million on higher compensation, commercial-preparedness, and legal costs. Cash, cash equivalents and investments totaled $373.4 million as of March 31, 2026, and the company believes this will fund operations into 2028.
Clinically, Definium has completed enrollment in its Phase 3 Emerge (MDD) and Voyage (GAD) studies, with topline data expected in late 2Q and early 3Q 2026, respectively, and updated late 3Q 2026 timing for Panorama (GAD). The DT120 ODT program is being expanded into PTSD with the Phase 3 Haven study expected to initiate in 2027.
Definium Therapeutics provided a detailed update on its lead candidate DT120 ODT (lysergide tartrate), an orally disintegrating psychedelic formulation being developed for generalized anxiety disorder (GAD), major depressive disorder (MDD) and posttraumatic stress disorder (PTSD). The company highlighted that three pivotal Phase 3 topline readouts are expected within roughly six months: the Emerge study in MDD in late 2Q 2026, the Voyage study in GAD in early 3Q 2026, and the Panorama study in GAD in late 3Q 2026. Emerge is fully enrolled with 149 participants, Voyage with 214 participants, and Panorama’s target enrollment has been updated to 200 after a blinded sample size re‑estimation that preserved high statistical power. A Phase 3 Ascend study in MDD plans to enroll 175 participants, while the Haven Phase 3 PTSD trial is expected to start in 2027 with about 200 participants.
Phase 2b data in GAD showed rapid and durable symptom improvement after a single 100 µg dose of DT120 ODT, with a 21.9‑point reduction on the HAM‑A anxiety scale at Week 12 and 48% of participants in remission, and a favorable tolerability profile dominated by mild, dosing‑day adverse events. Phase 3 designs use single‑dose, double‑blind cores with 40‑week extension phases to characterize durability and retreatment patterns, and employ adaptive sample size re‑estimation to maintain power. Management positions DT120 ODT as a potential best‑in‑class, multi‑billion‑dollar commercial opportunity supported by a scalable, single‑visit dosing model, existing psychiatric delivery infrastructure, and payer feedback referencing Spravato as a pricing and access analog. The company reports $411 in cash, cash equivalents and investments as of December 31, 2025 and expects its cash runway to extend into 2028 based on its current operating plan and anticipated milestones.
Definium Therapeutics reported a larger full-year 2025 net loss of $183.8 million, compared with $108.7 million in 2024, as it ramped late-stage development for its psychedelic-based therapies.
Cash, cash equivalents and investments rose to $411.6 million as of December 31, 2025, up from $273.7 million a year earlier, helped by a $259 million equity financing completed in the fourth quarter. The company expects this cash to fund operations into 2028.
Research and development expenses increased to $117.7 million from $65.3 million, driven mainly by higher DT120 program spending and expanded R&D staffing. General and administrative costs rose to $48.6 million from $38.6 million, reflecting greater professional services, pre-commercial efforts, and personnel expenses.
Definium highlighted progress across four Phase 3 trials of DT120 ODT in major depressive disorder and generalized anxiety disorder, with its Emerge MDD study fully enrolled and multiple topline readouts anticipated in 2026. It also advanced DT402 into a Phase 2a study for autism spectrum disorder.
Definium Therapeutics, Inc. reported a change to its board of directors. On January 28, 2026, the board expanded from six to seven members and appointed Roger Adsett as a director effective January 29, 2026, with a term running until the 2026 annual general meeting, or until a successor is chosen or he departs earlier.
Adsett was not assigned to any board committees at this time. Under the company’s non-employee director compensation policy, he will receive an annual cash retainer of $40,000, paid quarterly on a pro-rata basis. He also received an option to purchase 50,000 common shares, vesting one-third on the first anniversary of the grant date and the remainder in equal monthly installments thereafter, subject to continued board service.
The option grant was issued under the company’s 2025 Equity Incentive Plan. The filing notes there are no special arrangements leading to his appointment and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., reported estimated preliminary cash, cash equivalents and investments of about $412 million as of December 31, 2025, shared in a corporate presentation posted online. This figure is unaudited, may change, and has not been reviewed or examined by KPMG LLP.
The company has officially changed its corporate name to Definium Therapeutics, Inc., with board approval and updated British Columbia corporate records. The rebranding is described as aligning with its next phase as a psychiatric drug development leader. Common shares will keep the same CUSIP and begin trading on the Nasdaq under the new ticker “DFTX” starting January 13, 2026, with no action required from shareholders.
Mind Medicine (MindMed) Inc. (MNMD) furnished an update via an 8-K announcing it issued a press release with financial results for its second quarter ended September 30, 2025, including information about a conference call to discuss the results and recent corporate highlights.
The company also posted an updated corporate presentation on its website. The press release is provided as Exhibit 99.1, and the presentation as Exhibit 99.2.
Mind Medicine (MindMed) Inc. (MNMD) announced an underwritten public offering of 18,375,000 common shares at $12.25 per share. Underwriters were granted a 30‑day option to buy up to 2,756,250 additional shares at the same price, which was exercised in full on October 30, 2025. Gross proceeds are expected to be approximately $258.9 million, with estimated net proceeds of $242.8 million after discounts and expenses. The offering is expected to close on October 31, 2025.
The company plans to use net proceeds to fund research and development of its product candidates, as well as for working capital and general corporate purposes. A portion may be used for potential investments or acquisitions, though there are no current agreements. Directors and executive officers agreed to a 90‑day lock‑up. The offering was made under MindMed’s effective shelf registration statement on Form S‑3 with a base prospectus and prospectus supplement.
Mind Medicine (MindMed) Inc. disclosed preliminary liquidity. The company reported estimated unaudited cash, cash equivalents and investments of approximately $209.1 million as of September 30, 2025. This figure was included in a prospectus supplement and an updated corporate presentation posted on October 29, 2025.
Management emphasized that the estimate is preliminary and subject to completion, and that the company’s independent auditor, KPMG LLP, has not audited, reviewed, or compiled this information. The company noted that adjustments may be required once customary procedures are completed.
MindMed also filed the corporate presentation as Exhibit 99.1, making the materials available for investors seeking additional context on its financial position.
Mind Medicine (MindMed) Inc. filed a report stating that it has issued a press release about new clinical data. On September 4, 2025, the company announced the publication of results from its Phase 2b clinical trial of MM120 (Lysergide D-Tartrate) for Generalized Anxiety Disorder in the Journal of the American Medical Association. The related press release is included as an exhibit to provide more detail on the trial results and their context.